NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Conditions
Head and Neck Cancer
Conditions: official terms
Carcinoma, Squamous Cell - Head and Neck Neoplasms
Conditions: Keywords
Oral cavity Cancer, Oropharynx Cancer
Study Type
Interventional
Study Phase
Phase 1
Study Design
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: NBTXR3
Type: Device
Overall Status
Recruiting
Summary
RATIONALE: Cancers of the oral cavity represent 30% of head and neck carcinomas in the western world. The oropharynx is the posterior continuation of the oral cavity and connects with the nasopharynx (above) and laryngopharynx (below). It is also a frequent site of primary head and neck cancers. These structures play a crucial role in swallowing, breath and speech. Locally advanced oropharyngeal cancers can obstruct the air flow or infiltrate muscles or nerves, which significantly disturb local functions. The incidence of Head and Neck Squamous Cell Cancer in patients older 65 years is high, 47% occurred in this population as recorded by the Surveillance, Epidemiology, and End Results registries in the United States. Regarding the therapeutic strategies, the association of radiotherapy with chemotherapy or biologics has demonstrated significant improvement of outcomes with the drawback of higher toxicity, or as demonstrated by 2 meta-analyses, without survival improvement in older patients. NBTXR3 and radiation therapy may increase the cancer cell killing and complete tumor shrinkage allowing a definitive treatment and preservation of local structures and functions in patients older 65 years, who cannot receive cisplatin.
Detailed Description
Patients will receive a single administration of NBTXR3 on day 1, either as an intra-arterial or intratumor injection, followed by Intensity Modulated Radiation Therapy starting 24 hours later (day 2), and up to completion of 7 weeks, i.e. 70 Grays, 2Grays/fraction. Patients whose tumor has completely shrunk will be followed for the post-radiotherapy evaluation up to the End of Treatment visit. Those patients whose tumor has not shrunk more than 50% of the baseline size, will stop the radiotherapy and may have a salvage tumor surgery. Then, all patients will be followed every 8 weeks, for the safety evaluation and cancer disease status until the end of the study.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 65 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients aged ≥ 70 years old

- Patients aged ≥ 65 years old and < 70 years old with contra-indication to cisplatin

- Patients that are intolerant to cisplatine or cetuximab or that cannot receive the combination of chemoradiation

- Histologically or cytologically confirmed Squamous Cell Carcinoma (SCC) of the oral cavity or oropharynx

- T3 or T4 primary tumor or Stage III or IVA according to American Joint Committee on Cancer guidelines (AJCC, 7th Edition, 2010)

- No evidence of distant metastatic disease, as determined by a negative Positron Emission Tomography (PET Scan) or Computerized Tomography (CT Scan)

- Clinically eligible for either intra-arterial or intratumor implantation by injection

- KPS Karnofsky performance status) ≥ 70

- Adequate function of Bone marrow:

- White Blood Cell (WBC) > 3.0 x 109/l

- Absolute neutrophil count (ANC) >= 1.0 x 109/l

- Platelet count >= 100 x 109/l

- Hemoglobin >= 9.0 g/dL

- Adequate function of Kidney:

- Creatinine <= 1.5 x ULN or creatinine clearance >= 50 mL/min/1.73m²

- Adequate function of liver:

- AST (Aspartate aminotransferase) <= 5 x ULN

- ALT (Alanine aminotransferase) <= 5 x ULN

- Bilirubin <= 1.5 x ULN

Exclusion Criteria:

- Written Informed Consent not obtained, signed and dated

- Prior radiotherapy to any area within the planned radiotherapy field

- Tumor-related dyspnea

- Tumor ulceration which implies vascular risk

- Non measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria

- History of stroke, Coronary Artery Bypass Graft (CABG), or significant blockage of carotid arteries or coronary arteries or current blockage of coronary or carotid arteries equal to or in excess of 50% blockage

- Uncontrolled intercurrent illness including, but not limited to,ongoing or active severe infection, symptomatic congestive heart failure, acute coronary syndrome, etc.

- Medical history of life-threatening ventricular arrhythmia

- Prior or concurrent non-head and neck malignancies, excluding adequately treated basal or squamous cell cancer of the skin, and in situ cervical cancer, and any other cancer from which the subject has been cancer free for 5 years

- Concurrent treatment with any other anticancer therapy, including chemotherapy, immunotherapy, targeted therapy, gene therapy, or patients planning to receive these treatments during the study

- Patients unable to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures or those with severe psychiatric illness/social situations that would limit compliance with study requirements

- Patients participating in another clinical investigation at the time of signature of the informed consent
Locations
Institut Curie
Paris, France
Status: Recruiting
Contact: Christophe LE TOURNEAU, MD-PhD
START MADRID, Hospital Fundacion Jimenez Diaz
Madrid, Spain
Status: Recruiting
Contact: Victor MORENO, MD-PhD
START MADRID, Hospital Universitario Madrid Norte Sanchinarro
Madrid, Spain
Status: Recruiting
Contact: Emiliano CALVO, MD-PhD
Start Date
August 2013
Completion Date
August 2016
Sponsors
Nanobiotix
Source
Nanobiotix
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page